Vivimed Labs Limited
6.23
INR
-0.12
(-1.89%)
Vivimed Labs Limited
BSE:VIVIMEDLAB
(Bombay Stock Exchange)
Recent
price
6.23
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Vivimed Labs Ltd, headquartered in Hyderabad, India and founded in 1988, manufactures and supplies specialty chemicals and pharmaceutical products to global markets in over 50 countries. The company produces active pharmaceutical ingredients including generic APIs and intermediates via its subsidiary Uquifa with facilities in Spain and Mexico; finished dosage formulations such as tablets, capsules, syrups, ointments and nasal sprays for areas including diabetes, tuberculosis, oncology, nutritional supplements, hygiene and infectious diseases; and specialty chemicals encompassing active ingredients for home and personal care like triclosan preservatives, sunscreens, anti-wrinkle agents, skin lighteners, anti-dandruff compounds, hair growth promoters, hair conditioners, anti-microbials and oral care products, alongside hair dyes under the Jarocol brand, photochromic dyes under Reversacol, imaging chemicals, nutraceuticals, natural actives, colors and dyes. It operates manufacturing plants in India including sites in Hyderabad, Haridwar, Kashipur and Bidar, R&D labs in India and the UK, and strategic business units Vivimed Labs USA Inc and Vivimed Labs Europe with a marketing office in China; the company provides contract development and manufacturing organization services in APIs and formulations targeting pharmaceutical firms, personal care brands and industrial clients primarily in the US, Europe, erstwhile USSR countries, Africa and Asia. Recent developments include the 2023 acquisition of a US FDA-approved solid oral dosage facility in Alathur, Tamil Nadu from Actavis Pharma Manufacturing for Rs 122 crore along with two Abbreviated New Drug Applications to bolster generics revenue; in October 2025, its debt obligations were assigned from State Bank of India to Rare Asset Reconstruction Ltd encompassing all security interests to support financial restructuring; and ongoing quarterly financial reporting shows net sales of Rs 25.61 crore for Q4 FY2025 with persistent losses amid sales declines, reflecting efforts to stabilize operations through asset optimization and compliance-focused expansions.